Serum lipid level in Iranian patients with psoriasis

被引:44
作者
Farshchian, M.
Zamanian, A.
Farshchian, M.
Monsef, A-R
Mahjub, H.
机构
[1] Hamedan Univ Med Sci, Fac Med, Hamadan, Iran
[2] Hamedan Univ Med Sci, Dept Pathol, Hamadan, Iran
[3] Hamedan Univ Med Sci, Fac Hlth, Hamadan, Iran
[4] Sina Hosp, Dept Dermatol, Hamadan, Iran
关键词
psoriasis; lipids; inflammation; dyslipidemia; blood glucose; cardiovascular diseases;
D O I
10.1111/j.1468-3083.2006.02099.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Psoriasis is a common, chronic, inflammatory and proliferative skin disease associated with abnormal lipid metabolism. Previous studies have demonstrated that patients with psoriasis may have an increased risk of occlusive vascular disease. Objectives The aim of this study was to determine lipid profile in Iranian patients with psoriasis. Subjects and methods A cross-sectional study was performed in 30 patients with approved psoriasis diagnosis attending the Dermatology Outpatient Department at Sina Hospital, Hamedan, Iran and 30 matched healthy individuals. Fasting blood sugar (FBS), triglyceride, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) were measured using standard enzymatic method. The psoriasis activity was evaluated by psoriasis area and severity index (PASI Index). Results FBS levels were higher in patients with psoriasis diagnosis but the differences were not significant (P-value = 0.284). There were no significant differences between serum levels of triglyceride and cholesterol in two groups. There were no differences in lipoproteins (HDL, LDL, VLDL) compared with control subjects. (P-value > 0.05) PASI Index and lipid profile did not have any significant correlation. The correlation between duration of disease and LDL were significant (P-value = 0.033). Conclusion Lipid profile in Iranian patients with psoriasis did not differ compared with control-matched subjects.
引用
收藏
页码:802 / 805
页数:4
相关论文
共 26 条
[1]   Lipids and CVD management: towards a global consensus [J].
Ballantyne, C ;
Arroll, B ;
Shepherd, J .
EUROPEAN HEART JOURNAL, 2005, 26 (21) :2224-2231
[2]  
Behnam Shahrad M, 2005, Skinmed, V4, P174
[3]   C-reactive protein and α2-macroglobulin plasma activity in medium-severe and severe psoriasis [J].
Chodorowska, G ;
Wojnowska, D ;
Juszkiewicz-Borowiec, M .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2004, 18 (02) :180-183
[4]  
Çimsit G, 1998, BRIT J DERMATOL, V138, P917
[5]  
ENA P, 1985, ACTA CARDIOL, V40, P199
[6]   SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[7]   HYPERTRIGLYCERIDEMIA IN PATIENTS WITH PSORIASIS TREATED WITH CYCLOSPORINE [J].
GROSSMAN, RM ;
DELANEY, RJ ;
BRINTON, EA ;
CARTER, DM ;
GOTTLIEB, AB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (04) :648-651
[8]   DISEASE CONCOMITANCE IN PSORIASIS [J].
HENSELER, T ;
CHRISTOPHERS, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 32 (06) :982-986
[9]   Acitretin in psoriasis: An overview of adverse effects [J].
Katz, HI ;
Waalen, J ;
Leach, EE .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (03) :S7-S12
[10]   Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis [J].
Kural, BV ;
Örem, A ;
Çimsit, G ;
Yandi, YE ;
Calapoglu, M .
CLINICA CHIMICA ACTA, 2003, 328 (1-2) :71-82